MiR-122 continues to blaze the trail for microRNA therapeutics

Molecular Therapy

Volumn 18, Issue 2, 2010, Pages 240-242

  Haussecker, Dirk ^a   Kay, Mark A ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERFERON; MICRORNA; MICRORNA 122; PLACEBO; RIBAVIRIN; SPC 3649; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; BINDING SITE; CHIMPANZEE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; GENE FUNCTION; GENE MUTATION; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIPID METABOLISM; LIVER CELL; LOW DRUG DOSE; NONHUMAN; NOTE; PATIENT COMPLIANCE; REPLICON; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA ISOLATION; VIRUS REPLICATION; VIRUS TITRATION;

EID: 76249088041     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2009.313     Document Type: Note

References (15)

1. Lagos-Quintana, M, Rauhut, R, Yalcin, A, Meyer, J, Lendeckel, W and Tuschl, T (2002). Identifcation of tissue-specifc microRNAs from mouse. Curr Biol 12: 735-739.
2. Chang, J, Nicolas, E, Marks, D, Sander, C, Lerro, A, Buendia, MA, et al. (2004). miR-122, a mammalian liver-specifc microRNA, is processed from Hcr mRNA and may downregulate the high affnity cationic amino acid transporter CAT-1. RNA Biol 1: 106-113.
3. Krützfeld, J, Rajewski, N, Braich, R, Rajeev, KG, Tuschl, T, Manoharan, M, et al. (2005). Silencing of micro RNAs in vivo with antagomirs. Nature 438: 685-689.
4. Coulouarn, C, Factor, VM, Andersen, JB, Durkin, ME and Thorgeirsson, SS (2009). Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene 28: 3526-3536.
5. Esau, C, Davis, S, Murray, SF, Yu, XX, Pandey, SK, Pear, M, et al. (2006). miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 3: 87-98.
6. Jopling, CL, Yi, M, Lancaster, AM, Lemon, SM and Sarnow, P (2005). Modulation of hepatitis C virus RNA abundance by a liver-specifc microRNA. Science 309: 1577-1581.
7. Elmén, J, Lindow, M, Schütz, S, Lawrence, M, Petri, A, Obad, S, et al. (2008). LNA-mediated microRNA silencing in non-human primates. Nature 452: 896-899.
8. Lanford, RE, Hildebrandt-Eriksen, ES, Petri, A, Persson, R, Lindow, M, Munk, ME, et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science; e-pub ahead of print 3 December 2009.
9. Ye, J, Wang, C, Sumpter, R Jr, Brown, MS, Goldstein, JL and Gale, M Jr (2003). Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation. Proc Natl Acad Sci USA 100: 15865-15870.
10. Kapadia, SB and Chisari, FV (2005). Hepatitis C virus RNA replication is regulated by host geranylgerany-lation and fatty acids. Proc Natl Acad Sci USA 102: 2561-2566.
11. Chen, CM, He, Y, Lu, L, Lim, HB, Tripathi, RL, Middleton, T, et al. (2007). Activity of a potent hepatitis C virus polymerase inhibitor in the chimpanzee model. Antimicrob Agents Chemother 51: 4290-4296.
12. Ferenci, P (2004). Predicting the therapeutic response in patients with chronic hepatitis C: the role of viral kinetic studies. J Antimicrob Chemother 53: 15-18.
13. Hézode, C, Forestier, N, Dusheiko, G, Ferenci, P, Pol, S, Goeser, T, et al. and PROVE2 Study Team (2009). Telaprevir and peginterferon with or without riba-virin for chronic HCV infection. N Engl J Med 360: 1839-1850.
14. Watanabe, T, Umehara, T and Kohara, M (2007). Therapeutic application of RNA interference for hepatitis C virus. Adv Drug Deliv Rev 59: 1263-1276.
15. Bai, S, Nasser, MW, Wang, B, Hsu, SH, Datta, J, Kutay, H, et al. (2009). MicroRNA-122 inhibits tum-origenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. J Biol Chem 284: 32015-32027.